Glycan-based at-home treatment to shorten painful VOEs in sickle cell disease
Official title: A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease
Funded at Ihp Therapeutics, INC. · NIH-11402594 · Data updated 2026-11-12
A new at-home therapy called IHP-102 aims to modify the disease’s pain crises in adults with sickle cell disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ihp Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Carlos, UNITED STATES) |
| Project start | September 18, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $433,322 |
| NIH project number | 5UH3NS134781-03 |
| Project ID | NIH-11402594 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with sickle cell disease who experience vaso-occlusive pain crises and are seeking disease-modifying, at-home treatment.
✕Less likely to help
Patients without VOEs or those without access to home-treatment delivery may not benefit.
What this research studies
This grant supports developing IHP-102, a home-use therapy designed to reduce the intensity and duration of vaso-occlusive events in adults with sickle cell disease. The approach targets multiple mechanisms behind pain, including P-selectin and complement pathways. The project focuses on enabling patients to self-manage painful episodes outside of hospital settings, potentially reducing reliance on opioids. If successful, it could change how VOEs are treated by addressing the underlying biology rather than just symptom relief.
Why it matters
Potential benefit: If successful, patients could experience fewer and less severe pain crises and gain greater independence in managing VOEs at home.
How similar studies have gone: Previous approaches have struggled to modify VOE; this project is exploring a novel glycan-based strategy with preclinical/early clinical considerations.
Where this research is happening
-
Ihp Therapeutics, INC.
San Carlos, United States Active
Researchers
- Principal investigator: Paderi, John — Ihp Therapeutics, INC.
- Study coordinator: Paderi, John
Related research
Other NIH-funded projects on the same topics.
-
Digital twins of the spleen to help design better therapies for sickle cell disease
A computer-driven replica of the spleen is being developed to speed up creating safer and more effective treatments for people with sickle cell disease.
-
Accelerating hydroxyurea use for sickle cell disease in Nigeria
A pragmatic study in Nigeria aims to help doctors use hydroxyurea more consistently for people with sickle cell disease.
-
Immune and nerve signals behind acupuncture relief for sickle cell pain
This NIH grant explores how acupuncture helps reduce pain and opioid use for people with sickle cell disease.
-
Mindfulness-based Support for Pain and Sleep in Young People with Sickle Cell Disease
A digital mindfulness program is being tailored for adolescents and young adults with sickle cell disease to help with pain and sleep and is being tested for practicality and early effectiveness.
-
How diet affects white blood cells and sickle cell disease
A study looks at how nutrition, from early life to adulthood, influences sickle cell disease by examining neutrophils and disease severity in people with SCD and in a mouse model.
-
Nutrition-based plan to ease pain in sickle cell disease
A nutrition-based approach is being tested to reduce pain for people living with sickle cell disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.